'Reduced Effectiveness'; Some Lots of Tydemy Recalled
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
WEDNESDAY, Aug. 2, 2023 -- Certain lots of the prescription birth control pill Tydemy may be less effective than expected, potentially resulting in an unintended pregnancy, because the pills do not contain enough of an inactive ingredient.
The U.S. Food and Drug Administration warned consumers about the issue Tuesday following a company announcement on July 29.
Two lots of Tydemy (drospirenone/ethinyl estradiol/levomefolate calcium) made by Lupin Pharmaceuticals do not contain the correct level of ascorbic acid, the FDA noted. Lots L200183 and L201560, in 28-dose blister packs, were distributed throughout the United States between June 3, 2022, and May 31, 2023.
"To date, Lupin has received no reports of adverse events related to either recalled batches," the company noted. "Regardless, Lupin is recalling these two batches because if there were a significant reduction in the amount of inactive content (ascorbic acid), this could potentially impact the effectiveness of the product which could potentially result in unexpected pregnancy."
Patients should continue taking their medication, the FDA said, but they should also immediately contact their health care provider for advice about an alternative method of birth control.
The FDA also encouraged health care providers and patients to report any adverse events or quality problems with this or other medications to the agency's MedWatch Adverse Event Reporting program.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
AAN Issues Guideline for Use of Antiseizure Meds in People of Childbearing Potential
FRIDAY, May 17, 2024 -- In a practice guideline issued by the American Academy of Neurology, along with the American Epilepsy Society and the Society for Maternal-Fetal Medicine...
Transient Increase Seen in Contraceptive Use After Dobbs Decision
MONDAY, April 15, 2024 -- A transient increase in contraceptive use was seen following the Dobbs v Jackson Women's Health Organization decision, with a return to overall downward...
Birth Rate in United States Remained Unchanged From 2021 to 2022
THURSDAY, April 4, 2024 -- The birth rate in the United States was essentially unchanged from 2021 to 2022, according to the April 4 National Vital Statistics Reports, a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.